12-132023

Zuberitamab Injection (Anruixi®), BioRay’s first self-developed CD20-targeted Type 1 innovative biological product, has been successfully included in the National Medical Insurance Drug List 2023

On December 13, BioRay Biopharmaceutical Co., Ltd. announced that Zuberitamab Injection (trade name: Anruixi®), its first self-developed and produced type 1 anti-CD20 innovative biological product, has been successfully included in the National Basic Medi

read more

12-122023

BioRay Biopharmaceuticals’ Adalimumab Biosimilar Approved for Marketing in Pakistan

On December 12, BioRay Biopharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that its adalimumab biosimilar, developed in-house by its wholly-owned subsidiary Hisun Biopharmaceutical Co., Ltd., and registered in Pakistan by its local p

read more

05-242023

BioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1

Shanghai, China, May 24, 2023 /PRNewswire/--BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the Investigational New Drug (IND) application for the clinical trial of its proprietary BRY812, a novel antibody-drug conjugate

read more

05-172023

Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a Class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China

Recently, BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as "Bioray") announced that its independently developed Class I innovative therapeutic biological product, Zuberitamab Injection (trade name: Anruixi®), indicated for the treatment of CD2

read more

01-042023

BioRay Pharmaceutical Announces USD218 Million Strategic Financing Round

January 4, 2023 -- BioRay Pharmaceutical Co., Ltd., China’s leading autoimmune-focused biopharmaceutical firm, announced it has entered into definitive agreements for a strategic round of financing at a pre-money valuation of RMB13 billion (USD1.9 billi

read more

07-202022

BioRay Announces First-Patient-In for Phase I Clinical study of BR105 in patients with advanced Malignant Tumors

BioRay will push forward with our research and development projects in the field of popular targets for tumor immunity and autoimmunity to benefit patients.

read more

01-122022

BioRay announces IND approval for the Phase I self-developed Category 1 innovative drug BR 105 study

The approval of BR105 injection in clinical trials will further enrich BioRay's product pipeline.

read more

01-072022

The New Drug Application of BioRay’s Zuberitamab Injection has been accepted by China's National Medical Products Administration

BioRay announced that NMPA) had accepted the New Drug Application for the self-developed Category 1 innovative drug Zuberitamab (R&D Code: HS006, Trade name: Anruixi) for the first-line treatment of CD20 Positive Non-Hodgkin lymphoma (Acceptance No. CXSS2

read more

12-022021

BioRay Announces First-Patient-In for Phase II Clinical study of Zuberitamab in Patients with Primary immunologic thrombocytopenic purpura

BioRay announced that the first patient with Primary immunologic thrombocytopenic purpura (ITP) had been dosed in the Phase II Clinical trial of self-developed Zuberitamab (development code: HS006).

read more

09-282021

BioRay Infliximab for Injection (Anbaite®) received marketing authorization

BioRay announced that the National Medical Products Administration (NMPA) of China approved the application for marketing of its own human-mouse chimeric monoclonal antibody targeting human tumor necrosis factor-α (TNF-α), Infliximab for Injection (Anbait

read more